The Motley Fool
05 Sept 2026, 17:00 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Ares Capital's non-accrual loan rate increased to 2.4% of total investments at amortized cost in Q2. — Rising non-accruals indicate early stress in the loan portfolio and can potentially threaten dividend stability.
-0.40President Jim Miller warned that non-accrual rates are likely to undergo a 'reversion toward the mean' after a period of historical lows. — Management's own expectation of increasing defaults suggests the upward trend in non-accruals will persist.
-0.30Ares Capital's non-accrual rate of 2.4% remains below its historical average of 3% and the BDC industry average of 4%. — Comparing current stress to historical norms suggests the portfolio is still relatively healthy compared to peers.
+0.20Continue reading
6 related stories
Top 1 mover · tap to explore
The company's top 10 investments represent only 10.5% of its portfolio, significantly lower than the BDC peer average of 22.2%. — Higher diversification reduces the idiosyncratic risk of a single large loan default impacting the overall portfolio.
+0.20Which stocks this story touches
The company is facing headwinds from rising interest rates and an uptick in non-accrual loans, though its diversification and track record provide some cushion.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1d ago
